Skip to main content

Home  About Us  Services  Experience  Contact Us  Site Map   
What We Do > Principals >  
Principals                                                                                                                                                                  
 

Benjamin D. Schwartz, M.D., Ph.D.

 

Dr. Benjamin D. Schwartz earned his BA degree summa cum laude from Columbia College and his M.D. degree and Ph.D. degree in Immunology from the Albert Einstein College of Medicine in New York. He completed his residency and internship at Bronx Municipal Hospital Center. He then spent two years as a Research Associate in the Laboratory of Immunology at the National Institutes of Allergy and Infectious Diseases of the NIH, and subsequently joined the faculty of the Department of Medicine at Washington University School of Medicine in St. Louis, Missouri, where he was also an Investigator of the Howard Hughes Medical Institute, and Chief of Rheumatology at Jewish Hospital. In 1991, he became Director of Immunology at Monsanto Corporate Research and oversaw a variety of basic research programs to identify drug candidates to treat autoimmune diseases.

Dr. Schwartz joined Monsanto’s GD Searle Unit as Senior Director within the Arthritis Franchise and designed and directed several of the clinical trials which contributed to the approval of Celebrex®. He then directed the clinical development program for Bextra®. In 1999, he co-founded The Camden Group. Dr. Schwartz is also a Rheumatologist and Professor of Clinical Medicine at Washington University School of Medicine, and Attending Physician at Barnes-Jewish Hospital in St. Louis. He is Board Certified in Rheumatology, Internal Medicine, and Allergy and Immunology. He has been selected as one of the Best Doctors in America for 2005 -2010. Dr. Schwartz is a past President of the American Federation of Clinical Research. He has served on the Board of Directors of the Eastern Missouri Chapter of the Arthritis Foundation for over 25 years, and as the Chairman of the Board from 1992-1994. He has also served as the Chairman of the Research Council of the American College of Rheumatology (ACR), as Chairman of the NIH Allergy and Immunology Study Section, as a member of the Board of Directors of the ACR, as a member of the Board of Directors of the ACR Research and Education Foundation, as a member of the Research Committee of the National Arthritis Foundation, and as a member of several Blue Ribbon Committees addressing research issues for the ACR, Arthritis Foundation, and the NIH. Dr. Schwartz also serves on the Scientific Advisory Board of the Lupus Research Institute. He is the author of over 150 original research articles, review articles, and chapters in text books, and holds 3 patents as the result of work performed for Camden Group clients.

Laurel J. Mengle-Gaw, Ph.D.

 

Dr. Laurel J. Mengle-Gaw earned her BA degree with Highest Honors in Biology and Honors in Chemistry from the University of California, and her Ph.D. degree in Cancer Biology from Stanford University School of Medicine. Following postdoctoral research at the Medical Research Council Laboratory of Molecular Biology in Cambridge, England, she began her career in the pharmaceutical industry at Monsanto Co. Corporate Research and G.D. Searle in St Louis, Missouri, where she led basic research efforts to identify new drug candidates for disease targets in areas of strategic interest. Achievements included identification of new mechanistic targets, development of novel in vitro and in vivo model systems for candidate evaluation, and creation and direction of cross-functional research teams. In 1996, Dr. Mengle-Gaw joined G.D. Searle’s COX-2 inhibitor clinical research effort. In that capacity, she designed and managed multi-center phase 2 and 3 clinical trials for Celebrex®, including the single largest pre-approval trial of Celebrex®, led the clinical team responsible for implementation of the 50-study clinical program for Bextra®, and designed phase 1-3 clinical trials for the multiple indications for Bextra®. She was honored with awards for research excellence in both basic and clinical research from Monsanto Co. and G.D. Searle. She left G.D. Searle to co-found The Camden Group in 1999. Dr. Mengle-Gaw has authored over 40 original publications in peer-reviewed journals, invited reviews, and textbook chapters, spanning both basic and clinical science. She holds 3 patents as a result of work performed for Camden Group clients. She is a member of the American College of Rheumatology, American Pain Society, American Association of Immunologists, and the International Association for the Study of Pain.